The estimated Net Worth of Capital Equity Investments,... is at least 22 百万$ dollars as of 13 March 2015. Capital Investments owns over 350,000 units of Adamas Pharmaceuticals Inc stock worth over 13,662,692$ and over the last 11 years Capital sold ADMS stock worth over 8,362,504$.
Capital has made over 7 trades of the Adamas Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Capital sold 350,000 units of ADMS stock worth 6,030,500$ on 13 March 2015.
The largest trade Capital's ever made was selling 350,000 units of Adamas Pharmaceuticals Inc stock on 13 March 2015 worth over 6,030,500$. On average, Capital trades about 63,750 units every 14 days since 2014. As of 13 March 2015 Capital still owns at least 1,662,128 units of Adamas Pharmaceuticals Inc stock.
You can see the complete history of Capital Investments stock trades at the bottom of the page.
Over the last 11 years, insiders at Adamas Pharmaceuticals Inc have traded over 26,222,162$ worth of Adamas Pharmaceuticals Inc stock and bought 1,128,061 units worth 17,799,399$ . The most active insiders traders include Point Partners Llcjay Jeffr...、David L Mahoney、William W. Ericson. On average, Adamas Pharmaceuticals Inc executives and independent directors trade stock every 25 days with the average trade being worth of 254,236$. The most recent stock trade was executed by Vijay Shreedhar on 21 June 2021, trading 6,200 units of ADMS stock currently worth 31,992$.
Adamas Pharmaceuticals Inc. delivers innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. The company is a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.
Adamas Pharmaceuticals Inc executives and other stock owners filed with the SEC include: